Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IRLAB Therapeutics in connection with share issues
Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge advises L5 Navigation in connection with the acquisition of Lundaman Instrument

 L5 Navigation Systems AB has acquired the shares in Lundaman Instrument AB. Lundaman develops and supplies weighing systems for wheel loaders and forklift trucks, focusing on the construction, recycling, industrial and materials handling sectors.
May 13, 2026

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

 Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

 Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026